Pain Management, published by Future Medicine Ltd, is a premier journal that serves the fields of anesthesiology, pain medicine, and dentistry. With its ISSN 1758-1869 and E-ISSN 1758-1877, this journal is committed to advancing knowledge and practice through high-quality research articles, clinical studies, and expert reviews. The journal has established itself as a pivotal resource in pain management with a commendable impact factor and recognition in category quartiles, achieving Q2 rankings in Anesthesiology and Pain Medicine, as well as in miscellaneous Medicine and Dentistry categories as of 2023. Researchers and professionals will find a wealth of information in its comprehensive articles, which are essential for staying at the forefront of developments in pain management therapies and techniques. Although access is not open, the journal is recognized for its rigor and significance in shaping the future of pain management practices globally. Join the community of experts engaging in cutting-edge discussions by exploring the impactful research being published in this essential resource.

HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

GENERAL HOSPITAL PSYCHIATRY is a leading academic journal dedicated to the interdisciplinary fields of psychiatry and mental health, published by Elsevier Science Inc. With a substantial impact factor, this journal is recognized as a Q1 publication in its field, reflecting its significant contribution to advancing research and practice. Since its inception in 1979, GENERAL HOSPITAL PSYCHIATRY has provided a crucial platform for innovative studies, clinical findings, and discussions surrounding mental health care within a hospital setting. The journal addresses a wide range of topics, including psychiatric assessment, diagnosis, treatment interventions, and public health strategies, positioning itself at the forefront of psychiatric research. Though currently not open access, it strives to disseminate knowledge that is vital for healthcare professionals, researchers, and students aiming to enhance mental health outcomes. With an impressive convergence timeline extending to 2024, this journal is essential for anyone invested in the scholarly exploration of psychiatry.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.